128 related articles for article (PubMed ID: 27244269)
41. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection.
Cheung YK; Cheng SC; Sin FW; Xie Y
Vaccine; 2004 Dec; 23(5):629-38. PubMed ID: 15542183
[TBL] [Abstract][Full Text] [Related]
42. Production of immunogenic human papillomavirus-16 major capsid protein derived virus like particles.
Patel MC; Patkar KK; Basu A; Mohandas KM; Mukhopadhyaya R
Indian J Med Res; 2009 Sep; 130(3):213-8. PubMed ID: 19901429
[TBL] [Abstract][Full Text] [Related]
43. Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1.
Kuck D; Lau T; Leuchs B; Kern A; Müller M; Gissmann L; Kleinschmidt JA
J Virol; 2006 Mar; 80(6):2621-30. PubMed ID: 16501072
[TBL] [Abstract][Full Text] [Related]
44. [Expression, purification and immunogenicity analysis of HPV type 18 virus-like particles from Escherichia coli].
Xie M; Li S; Shen W; Li Z; Zhuang Y; Mo X; Gu Y; Wu T; Zhang J; Xia N
Sheng Wu Gong Cheng Xue Bao; 2009 Jul; 25(7):1082-7. PubMed ID: 19835152
[TBL] [Abstract][Full Text] [Related]
45. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
46. Control of HPV infection and related cancer through vaccination.
Tran NP; Hung CF; Roden R; Wu TC
Recent Results Cancer Res; 2014; 193():149-71. PubMed ID: 24008298
[TBL] [Abstract][Full Text] [Related]
47. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
Park JS; Oh YK; Kang MJ; Kim CK
J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
[TBL] [Abstract][Full Text] [Related]
48. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M
Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598
[TBL] [Abstract][Full Text] [Related]
49. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
Hantz S; Alain S; Denis F
Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
[TBL] [Abstract][Full Text] [Related]
50. The C-Terminal Arm of the Human Papillomavirus Major Capsid Protein Is Immunogenic and Involved in Virus-Host Interaction.
Li Z; Yan X; Yu H; Wang D; Song S; Li Y; He M; Hong Q; Zheng Q; Zhao Q; Gu Y; Zhang J; Janssen ME; Cardone G; Olson NH; Baker TS; Li S; Xia N
Structure; 2016 Jun; 24(6):874-85. PubMed ID: 27276427
[TBL] [Abstract][Full Text] [Related]
51. High-Level Production of Human Papillomavirus (HPV) Type 16 L1 in Escherichia coli.
Bang HB; Lee YH; Lee YJ; Jeong KJ
J Microbiol Biotechnol; 2016 Feb; 26(2):356-63. PubMed ID: 26608168
[TBL] [Abstract][Full Text] [Related]
52. [Construction and identification of the replication-deficient recombinant vaccinia virus co-expressing HPV type 16 L1 and L2 proteins].
Han L; Ren J; Liang Y; Tian H; Zhi H; Luo W; Lu Z; Wei L; Ruan L
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Sep; 16(3):256-60. PubMed ID: 12665934
[TBL] [Abstract][Full Text] [Related]
53. Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes.
Leder C; Kleinschmidt JA; Wiethe C; Müller M
J Virol; 2001 Oct; 75(19):9201-9. PubMed ID: 11533183
[TBL] [Abstract][Full Text] [Related]
54. Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.
Bissett SL; Godi A; Fleury MJ; Touze A; Cocuzza C; Beddows S
J Virol; 2015 Aug; 89(15):7748-57. PubMed ID: 25995264
[TBL] [Abstract][Full Text] [Related]
55. Whole recombinant Pichia pastoris expressing HPV16 L1 antigen is superior in inducing protection against tumor growth as compared to killed transgenic Leishmania.
Bolhassani A; Muller M; Roohvand F; Motevalli F; Agi E; Shokri M; Rad MM; Hosseinzadeh S
Hum Vaccin Immunother; 2014; 10(12):3499-508. PubMed ID: 25668661
[TBL] [Abstract][Full Text] [Related]
56. Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly.
Li M; Cripe TP; Estes PA; Lyon MK; Rose RC; Garcea RL
J Virol; 1997 Apr; 71(4):2988-95. PubMed ID: 9060658
[TBL] [Abstract][Full Text] [Related]
57. HPV16 L2 improves HPV16 L1 gene delivery as an important approach for vaccine design against cervical cancer.
Namvar A; Bolhassani A; Hashemi M
Bratisl Lek Listy; 2016; 117(3):179-84. PubMed ID: 26925750
[TBL] [Abstract][Full Text] [Related]
58. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
[TBL] [Abstract][Full Text] [Related]
59. [Immunological tests: Antibodies to human papillomavirus type 16 L1-capsids].
Matsumoto K
Nihon Rinsho; 2005 Jul; 63 Suppl 7():326-8. PubMed ID: 16111264
[No Abstract] [Full Text] [Related]
60. HPV vaccines.
Stanley M
Best Pract Res Clin Obstet Gynaecol; 2006 Apr; 20(2):279-93. PubMed ID: 16356772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
